Home Health A CDC study shows that the Pfizer COVID vaccine is 93% effective against hospitalizations in children aged 12 to 18.

A CDC study shows that the Pfizer COVID vaccine is 93% effective against hospitalizations in children aged 12 to 18.

by news dir

Dr. Salma Elfaki examines 16-year-old Diego Alvarez patients in the adolescent Moderna COVID-19 vaccine clinical trial conducted by Accel Research Sites in partnership with the Nona Pediatric Center in Orlando, Florida, on Sept. 25. 2021

Paul Hennessy | SOPA Images | LightRocket | Getty Images

The Centers for Disease Control and Prevention’s Pfizer said in a small study report. published on Tuesday that The viral coronavirus vaccine is 93% effective at preventing hospitalization in children 12 to 18 years old.

The CDC has tracked 464 COVID-19 patients ages 12 to 18 spread in 19 US children’s hospitals. from June to September This is during which the delta variable increases throughout the country. while about 72% of them have at least one underlying disease that may increase their chances of developing severe symptoms. Researchers found that 97% of those who ended up in the hospital were not vaccinated.

“These data suggest that increasing vaccination coverage in this group can reduce the incidence of severe COVID-19 in the United States,” CDC researchers wrote in their Morbidity and Mortality Weekly Report.

Of the coronavirus cases, six were vaccinated and 173 were not vaccinated, 43% needed intensive care, and 16% of seriously ill children were resuscitated with deaths. Two lives in the cohort according to the study.

The CDC’s findings are similar to those of a study conducted in Israel. It found that Pfizer’s COVID vaccine was nearly 92% effective in preventing hospitalizations in patients aged 12 to 15, but the Israeli study did not identify any cases. enough to measure the full effectiveness of the vaccine in COVID hospital admissions, the CDC wrote.

About 61 percent of the study participants came from the south, the CDC said, as the region experienced high levels of coronavirus transmission from June to September. The high concentrations of patients in the South may have contributed to the findings, the researchers said.

The Food and Drug Administration approved Pfizer’s COVID vaccine for anyone over 16 Aug. 23, leaving it on emergency use for children aged 12 to 15, pending further consideration. More than 104 million people in the United States have received the full range of Pfizer vaccines. While more than 9 million people have taken the Pfizer stimulant drug, the CDC reported Tuesday.

The CDC allows Pfizer sponsors for selected risk groups. The last month included people aged 65 and over, all adults at medical risk. and those who have faced coronavirus infection due to their work US health leader withhold approval of stimulant drugs for people aged 12 to 18, citing a higher likelihood of surviving coronavirus and worried about risks of two rare vaccine-induced heart conditions: myocarditis and pericarditis.

The researchers noted that the study was limited by a small sample size. This makes it impossible to measure the efficacy of the vaccine in patients with underlying medical conditions. They added that They were also unable to determine the efficacy of the vaccine against the different types of coronavirus and said some participants may have incorrectly provided their vaccination status information.

Pfizer is waiting for the Food and Drug Administration to approve the vaccine for children ages 5 to 11. The company released data in September that said its two-dose vaccine provided a “strong” immune response in the group. Younger children and the FDA can clear the shots later this month.

The CDC reports that 46% of children aged 12 to 15 in the United States are fully vaccinated against coronavirus, while 54% of children aged 16 to 17 received the full dose on Monday.

.

Related Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.